Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can early markers predict how atypical Parkinson's diseases progress?

NCT ID NCT07805967

Knowledge-focused Sponsor: Second Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This observational study follows 500 people with atypical parkinsonian syndromes, including multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration. Researchers track motor and non-motor symptoms and imaging changes every 6 months for up to 3 years. The goal is to map how these diseases naturally progress and to build a database that could reveal biomarkers with early predictive value.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify early markers that help diagnose atypical parkinsonian syndromes sooner and track their progression more accurately.
What could go wrong
As an observational study, it cannot test treatments. The 3-year follow-up may be too short to capture the full course of these slowly evolving diseases, and findings may not apply beyond the specific diagnostic criteria used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with multiple system atrophy (MSA) , dementia with Lewy bodies (DLB) , progressive supranuclear palsy (PSP) , or corticobasal degeneration (CBD) according to Chinese/international consensus diagnostic criteria . Follow-up period : 3 years , with clinical phenotypes and/or biomarkers assessed every 6 months .

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) . 2. DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) . 3. PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years . 4. CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb). Exclusion Criteria: 1. Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure . 2. Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Corticobasal degeneration (CBD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Corticobasal Degeneration corticobasal degeneration disorder Lewy body dementia Lewy Body Disease multiple system atrophy progressive supranuclear palsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Corticobasal degeneration (CBD) Dementia with lewy bodies (DLB) Multiple system atrophy Progressive supranuclear palsy (PSP)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Nantong University

    NOT_YET_RECRUITING

    Nantong, China

  • Affiliated Hospital of Yangzhou University

    NOT_YET_RECRUITING

    Yangzhou, Jiangsu, 225000, China

  • Changshu Hospital Affiliated to Nanjing University of Chinese Medicine

    RECRUITING

    Changshu, Jiangsu, 215500, China

  • Changxing people' s hospital

    NOT_YET_RECRUITING

    Huzhou, China

  • Deyang People's Hospital

    NOT_YET_RECRUITING

    Deyang, China

  • Jiangsu Province (Suqian) Hospital

    RECRUITING

    Suqian, Jiangsu, 223800, China

  • Jiangsu Province Official Hospital

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, 210000, China

  • Jiaxing Second Hospital

    NOT_YET_RECRUITING

    Jiaxing, Zhejiang, 314000, China

  • Mianyang 404 Hospital

    NOT_YET_RECRUITING

    Mianyang, Sichuan, 621000, China

  • The Affiliated Hospital of Xuzhou Medical University

    NOT_YET_RECRUITING

    Xuzhou, China

  • The First People's Hospial of Kunshan

    NOT_YET_RECRUITING

    Kunshan, Jiangsu, 215300, China

  • The Forth Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215000, China

  • The Forth People's Hospital of Zhenjiang

    RECRUITING

    Zhenjiang, Jiangsu, 212000, China

  • The Second Affiliated Hospital of Nantong University

    NOT_YET_RECRUITING

    Nantong, Jiangsu, 226000, China

  • The Second Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215000, China

  • The Second Affiliated Hospital of Xuzhou Medical University

    NOT_YET_RECRUITING

    Xuzhou, Jiangsu, 221000, China

  • The second People's Hospital of Huai'an

    NOT_YET_RECRUITING

    Huai'an, Jiangsu, 223001, China

  • Yancheng Third People's Hospital

    RECRUITING

    Yancheng, Jiangsu, 224000, China

  • Yantai Yuhuangding Hospital

    NOT_YET_RECRUITING

    Yantai, Shandong, 264000, China

  • Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine/Zhangjiagang Traditional Chinese Medicine Hospital

    NOT_YET_RECRUITING

    Zhangjiagang, Jiangsu, 215600, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.